



News Release

Dr. Neil Singla to present at the 6th Annual Pain Therapeutics Summit in San Jose, California October 3-4, 2012

***-Minimizing experimental error in analgesic research by
reducing placebo response and variability-***

PASADENA, CA, July 2, 2012 (BUSINESS WIRE) --

Dr. Neil Singla, MD, Founder & Chief Scientific Officer, Lotus Clinical Research, LLC will be giving a presentation entitled "Minimizing experimental error in analgesic research by reducing placebo response and variability" at the 6th Annual Pain Therapeutics Summit in San Jose, California October 3-4, 2012. This presentation will focus on patient education tools designed to enhance data accuracy and reduce placebo response.

A significant portion of an analgesic investigation's variability is produced secondary to cognitive gaps that the patient may have when interpreting the various protocol mandated scales and questions. All pharmaceutical companies spend a large amount of time perfecting their protocol and selecting/educating quality sites so that the efficacy of their drug can be statistically demonstrated. However, an equal amount of effort is rarely placed on patient education. This piece of the puzzle is the responsibility of the site and as such, we have developed educational materials to reduce placebo response and garner data that is as "true" as possible. This talk will discuss placebo response training and other ways to mitigate variability in analgesic clinical trials.

About Dr. Neil Singla

Dr. Neil Singla, the Founder and Chief Scientific officer for Lotus Clinical Research, is a nationally recognized key opinion leader in analgesic protocol design and implementation. He has published extensively and is a frequent lecturer for physicians, pharmaceutical companies and medical research institutes throughout the country. For the past several years, the main focus of Dr. Singla's academic endeavors has been to analyze and understand how the inherent variability in subjective endpoint clinical trials can be minimized. He has developed novel techniques for patient education designed to minimize variability, reduce placebo response and increase effect size. Dr. Singla also serves as Director of Clinical Research, Vice Chairman of the Institutional Review Board and Chairman of the Clinical Research Committee at Huntington Memorial Hospital.

About Lotus Clinical Research

Lotus Clinical Research®, LLC has developed proprietary materials for patient education and staff training that consistently increase effect size by minimizing variability and placebo response in subjective endpoint trials.

Established in 2001, Lotus operates a 40-bed, Phase 1-3 privately owned research unit located on the 675-bed Huntington Hospital campus in Pasadena, California. Over the past 11 years, Lotus has been inspected by the FDA on 3 occasions. All three of these not-for-cause audits results in positive comments with no 483s issued. Our position inside a major metropolitan hospital provides unprecedented access to all medical specialties / therapeutic areas and state of the art medical equipment. Our geographical location in greater Los Angeles County allows us to easily recruit from a large and ethnically diverse population of subjects.

Nearly all hospital based research units are owned by the parent institution, which inevitably leads to an extended contracting process and a pain staking local IRB review cycle. Lotus has a unique private ownership business model which allows it to contract independently and utilize a central IRB, bypassing institutional bureaucracy for rapid study starts. Our specialties include Analgesics (Acute and Chronic Pain), Phase 1/Proof-of Concept, Opioid-Induced Constipation, Hospital-based Populations and Post-Operative Nausea and Vomiting.

For more information, visit www.lotuscr.com.

Contact:

Kimberly Britt

Manager, Business Development

(619) 303-3383